Carsten Dan Ley (Carsten D Ley)

Publication Activity (10 Years)

Years Active: 2019-2022
Publications (10 Years): 5

Top Topics

Magnetic Resonance

Total Knee Arthroplasty

Diffusion Weighted

Top Venues

Haemophilia : the official journal of the World Federation of Hemophilia

Journal of thrombosis and haemostasis : JTH

This page only lists publications with an associated author ORCID identifier.

Publications

Gabi Overgaard Øvlisen, Peter Thygesen, Karin Nana Weldingh, Esther Bloem, Søren Skov, Kasper Almholt, Karin Maria Lövgren, Carsten Dan Ley, Thomas Lindebo Holm
CTLA4-Ig prevents development of neutralizing antibody formation after continuous treatment with human FVIII in HA rats. Haemophilia : the official journal of the World Federation of Hemophilia 28 (4) (2022)
Henrik Østergaard, Jacob Lund, Per J Greisen, Stine Kjellev, Anette Henriksen, Nikolai Lorenzen, Eva Johansson, Gustav Røder, Morten G Rasch, Laust B Johnsen, Thomas Egebjerg, Søren Lund, Henrik Rahbek-Nielsen, Prafull S Gandhi, Kasper Lamberth, Mette Loftager, Lisbeth M Andersen, Amalie C Bonde, Fabian Stavenuiter, Daniel E Madsen, Xun Li, Thomas Lindebo Holm, Carsten Dan Ley, Peter Thygesen, Haisun Zhu, Rong Zhou, Karina Thorn, Zhiru Yang, Mette B Hermit, Jais R Bjelke, Bjarne G Hansen, Ida Hilden
A factor VIIIa-mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice. Blood 138 (14) (2021)
Rikke Stagaard, Carsten Dan Ley, Kasper Almholt, Lisbeth Høier Olsen, Tom Knudsen, Matthew J Flick
Absence of functional compensation between coagulation factor VIII and plasminogen in double-knockout mice. Blood advances 2 (22) (2019)
Kåre Kryger Vøls, Mads Kjelgaard-Hansen, Carsten Dan Ley, Axel Kornerup Hansen, Maj Petersen
Bleed volume of experimental knee haemarthrosis correlates with the subsequent degree of haemophilic arthropathy. Haemophilia : the official journal of the World Federation of Hemophilia 25 (2) (2019)
Junjiang Sun, Eric W Livingston, Mie L Broberg, Peter B Johansen, Carsten Dan Ley, Tom Knudsen, Mirella Ezban, Ted Bateman, Paul E Monahan, Sarah Taves
Prophylactic administration of glycoPEGylated factor IX provides protection and joint outcome superior to recombinant factor IX after induced joint bleeding. Journal of thrombosis and haemostasis : JTH 17 (8) (2019)